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Abstract 
Splenic lymphoma without splenomegaly is
uncommon. We report the case of a 68-year-
old female who presented with fulminant B
symptoms and thrombocytopenia, only to be
found to have micronodular large B-cell lymph-
oma of the spleen post-mortem. Diagnosis of
this rare entity remains difficult and overall
prognosis is poor.
Introduction
Both Hodgkin’s disease and non-Hodgkin’s
lymphoma can present with overwhelming B
symptoms and pancytopenia can be associated
with either disease, particularly when there is
involvement of the bone marrow. Certain en-
tities are difficult to diagnose because of lack
of organomegaly, including intravascular non-
Hodgkin’s  lymphoma.  Splenic  lymphoma  is
usually associated with organomegaly; in the
uncommon  micronodular  non-Hodgkin’s  B-
cell lymphoma of the spleen, neither splenic
organomegaly nor obvious extra-splenic sys-
temic involvement is seen.
1
Case Report
The patient is a 68-year-old female who pre-
sented  with  mild  thrombocytopenia  and  an-
emia. Specifically, her platelet count was 114,
white  blood  cell  count  was  normal  at  4.5,
hemoglobin 10, hematocrit 30. She also had
high  serum  ferritin.  Her  chief  complaint
involved fatigue and lethargy. She had lost five
pounds in weight. She was also afflicted with
diabetes and hypertension. The patient had a
computerized  tomography  (CT)  scan  of  the
chest,  abdomen,  and  pelvis,  which  initially
showed a small pericardial effusion and small
pleural  effusions.  Subsequently,  the  patient
experienced fevers, chills, and night sweats.
Two separate bone marrow aspirates and biop-
sies were completed. These were both nega-
tive. There was some megakaryocyte hyperpla-
sia in the bone marrow biopsy; hence the diag-
nosis of idiopathic thrombocytopenic purpura
(ITP) was made as the platelet count progres-
sively ranged as low as 10. Antiplatelet anti-
bodies were negative. Fibrinogen was elevat-
ed, as was the D-dimer, consistent with a low-
grade disseminated intravascular coagulation
process. No schistocytes or spherocytes were
seen on the peripheral smear, although the
lactate  dehydrogenase  (LDH)  had  ranged
between 800-2000 during the entire disease
process.  Haptoglobin  always  fell  within  the
normal range. Over a period of four months,
she had transient responses to steroids, IVIG
therapy,  and  finally  was  placed  on  Rituxan.
The spleen had never been enlarged, although
the liver had been measured at 7 and 18.2 cm
in length without focal lesions. 
Because  she  continued  to  worsen,  the
patient was taken to lapartotomy for a splenec-
tomy. The spleen had never been enlarged, nor
had it shown any focal lesions on CT scans. At
the time of surgery, the splenic cut surface
was found to be nodular, with white sclerotic
nodules  ranging  from  <1  mm  to  0.25  cm
(Figure 1). Dense infiltrates of mononuclear
cells were seen, consistent with a large B-cell
lymphoma  (Figure  2A  and  B).  Immuno-
staining was positive for lymphomatoid cells
expressing CD20 and CD79a (Figure 3A and
B).  The  pathology  was  consistent  with  a
micronodular  variant  of  diffuse  large  B-cell
lymphoma of the spleen. 
Discussion
Splenic  micronodular  large  B-cell  lymph-
oma  is  recognized  now  as  a  distinct  entity,
diagnosed only with great difficulty.
1-4 Splenic
lymphomas usually are indolent when they are
splenic lymphomas with villous lymphocytes;
large-cell lymphomas occurring in microscop-
ic nodules within the spleen can exert, as in
this case, a variety of symptoms on the indi-
vidual, causing a gradual physiologic decline.
T cell/histiocyte-rich large B-cell lymphomas
of  the  spleen  can  present  with  a  similar
micronodular pattern, but this type of lymph-
oma is characterized by a few scattered neo-
plastic large B cells within a proliferation of
non-neoplastic T lymphocytes and histiocytes.
Our case was predominantly one with large B
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Figure 1. Macroscopic view of the spleen
showing a nodular surface, the white scler-
otic nodules ranging from <1 mm to 0.25
cm in size.
Figure 2. (A) Low-power microscopic view
of the spleen illustrating nodular infiltrates
of mononuclear cells (arrows), consistent
with  a  large  B-cell  lymphoma  (hema-
toxylin  and  eosin  stain;  magnification
20X). (B) High-power microscopic view of
the spleen demonstrating diffuse infiltrate
of  neoplastic  large  B-cells  (hematoxylin
and eosin stain; magnification 400X).
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cells within the nodules, without a significant
small-cell  component  and  only  occasionally
admixed T cells, as highlighted by the CD3
immunostain.
1
The primary problem remains the diagno-
sis. Perhaps early dynamic diagnostic imaging
(i.e. PET scanning) will provide some hint of
the localization of the problem, and thus allow
for  effective  treatment.  Splenic  biopsy  in  a
thrombocytopenic  patient  without  localizing
symptoms  is  ill-advised.  Occasionally,  the
community  oncologist  is  presented  with  a
patient who defies diagnosis, although one is
almost certain there is either an occult malig-
nancy or an occult infection. These patients
may have disabling B symptoms, cytopenias,
non-specific organ dysfunction, and a variety
of  other  non-specific  signs  and  symptoms.
Exhaustive searches for malignancies, infec-
tions,  and  collagen  vascular  disease  are
expensive  and  fruitless.  Often  patients  are
diagnosed only at necropsy. Splenic involve-
ment with lymphoma usually occurs with at
least  some  enlargement  of  the  spleen.  Our
patient gradually declined over a period of four
months and was never able to have an out-
patient PET scan. Certain uncommon entities
such  as  lymphocyte-depleted  Hodgkin’s  dis-
ease or true intravascular non-Hodgkin’s lymph-
omas can cause such disabling B symptoms
and gradual decline, and diagnosis is made
usually at autopsy.
5-9 Because of the relative
rarity  of  autopsies  outside  of  the  academic
setting, combined with the difficulty of diag-
nosis while the patient is alive, these entities
are, in all likelihood, underdiagnosed.
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Figure 3. High-power microscopic view of
the  spleen  demonstrating  positive  CD20
(A)  and  CD79a  (B)  immunostains  for  B
lymphocytes (magnification 400X).
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